A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis <scp>C</scp>: A multicenter study

Shimada, Noritomo; Tsubota, Akihito; Atsukawa, Masanori; Abe, Hiroshi; Ide, Tatsuya; Takaguchi, Koichi; Chuganji, Yoshimichi; Toyoda, Hidenori; Yoshizawa, Kai; Ika, Makiko; Satō, Yoshiyuki; Kato, Kazúo; Kumada, Takashi; Sakamoto, Choitsu; Aizawa, Yoshifusa; Sata, Michio

doi:10.1111/hepr.12323

Cited by 3 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multicenter study reported that SVR rate was significantly higher with 48 weeks than 24 weeks therapy in nonresponders ( 9 ). In Turkey, the duration of Telaprevir based TDR is 24 weeks; first 12 weeks all three agents and peginterferon and ribavirin for the remaining 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Telaprevir Experience From Turkey

et al. 2015

View full text Add to dashboard Cite

Background:In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1.Objectives:In Turkey, telaprevir has been used since March 2013. We aimed to evaluate results of patients with chronic hepatitis C treated with telaprevir, peginterferon and ribavirin.Patients and Methods:We evaluated 28 patients with genotype 1 chronic hepatitis C infection treated with triple drug regimen containing telaprevir, in three medical centers in Turkey, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded.Results:Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of Telaprevir based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized.Conclusions:Although more frequent and severe adverse effects, telaprevir has been promising for patients with treatment-experienced hepatitis C.

show abstract

Section: Discussionmentioning

confidence: 99%

Telaprevir Experience From Turkey

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, results of the few studies focusing only on treatment-experienced patients were less conclusive. In a Japanese cohort of 103 treatment-experienced patients, mono-infected with HCV-1b and receiving TVR, the IL28B variant, rs8099917, was an independent predictor of SVR [ 29 ]. In the RESPOND-2 study of BOC-based therapy in treatment-experienced patients (N = 207), rs12979860 C/C genotype was predictive of a good interferon response at week 4 but only a non-statistically significant trend was observed with SVR [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study

About¹,

Oudot-Mellakh²,

Niay³

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

BackgroundHuman genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.Patients and MethodsA total of 256 HCV-1 Caucasian treatment-experienced patients with compensated cirrhosis from the ANRS CO20-CUPIC cohort were genotyped for a total of 10 candidate SNPs in IL28B (rs12979860 and rs368234815), APOH (rs8178822, rs12944940, rs10048158, rs52797880, rs1801689 and rs1801690) and ITPA (rs1127354 and rs7270101). We tested the association of IL28B and APOH SNPs with sustained virological response and of ITPA SNPs with anemia related phenotypes by means of logistic regression assuming an additive genetic model.ResultsNone of the six APOH SNPs were associated with sustained virological response. The favorable alleles of the IL28B SNPs rs12979860 and rs368234815 were associated with sustained virological response (rs12979860: OR = 2.35[1.50–3.70], P = 2x10-4). Refined analysis showed that the effect of IL28B SNPs on sustained virological response was restricted to prior PegIFN/RBV relapse (OR = 3.80[1.82–8.92], P = 8x10-4). We also confirmed the association between ITPA low activity alleles and protection against early hemoglobin decline in triple therapy (P = 2x10-5).ConclusionOur results suggest that the screening of rs12979860 may remain interesting for decision making in prior relapse HCV-1 Caucasian patients with compensated cirrhosis eligible for a telaprevir- or boceprevir-based therapy.

show abstract

“…Shimada et al . recently reported that by extending PEG IFN and RBV therapy from 24 to 48 weeks, telaprevir‐based triple therapy improves the SVR to up to 68% in prior null responders . Thus, telaprevir is a therapeutic option for prior null responders.…”

Section: Discussionmentioning

confidence: 99%

Serum granulysin levels as a predictor of serious telaprevir‐induced dermatological reactions

Suda

Yamamoto

Nagasaka

et al. 2014

Hepatology Research

Self Cite

View full text Add to dashboard Cite

AbbreviationsDAAs, direct-acting antivirals; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug rash with eosinophilia and systemic symptoms; HCV, hepatitis C virus; CHC, chronic hepatites C; Peg-IFN, pegylated interferon; RBV, ribavirin; RVR, rapid virological response; SJS, Stevens--Johnson syndrome; SVR, sustained virological response; TPV, telaprevir; TEN, toxic epidermal necrolysis Financial disclosureThe authors declare that they have nothing to disclose regarding funding from the industry or conflicts of interest with respect to the manuscript. AbstractBackground: Telaprevir-based therapy for chronic hepatitis C patients is effective;

show abstract

A 48‐week telaprevir‐based triple combination therapy improves sustained virological response rate in previous non‐responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study

Abstract: T12PR48 improves the SVR rate in null responders, patients with the non-TT genotype, and null responders with a non-TT genotype.

Cited by 3 publications

References 38 publications

Telaprevir Experience From Turkey

Telaprevir Experience From Turkey

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study

Serum granulysin levels as a predictor of serious telaprevir‐induced dermatological reactions

Contact Info

Product

Resources

About